First-Line Combo Immunotherapy Improves PFS in High TMB Non-Small Cell Lung Cancer – Pharmacy Times
Immuno-Oncology News |
First-Line Combo Immunotherapy Improves PFS in High TMB Non-Small Cell Lung Cancer
Pharmacy Times “TMB has emerged as an important biomarker for the activity of immunotherapy. For the first time, this phase III study shows superior PFS with first-line combination immunotherapy in a predefined population of NSCLC patients with high TMB,” study … Opdivo, Yervoy Combination Outshines Chemotherapy in Non-Small Cell Lung Cancer BMS Validates Predictive Role of Tumor Mutation Burden in Phase 3 CheckMate -227 Program in First-Line Non-Small … |
